Update of January 20, 2021, CEREVANCE

This information may change depending on official recommendations.

Children with ITP, AHAI or Evans syndrome have not been reported to be at an excess risk of becoming infected with COVID or developing a serious infection from COVID, compared to the general population of their age, with the exception of some very rare contexts of primary immune deficiencies associated with autoimmune cytopenia.

To date, there are no published studies on anti-COVID vaccination in children under 16, which would show a benefit. Conversely, there is also no signal that allows us to suspect a risk of an outbreak of autoimmune diseases in the event of an anti-COVID vaccination.

For now, given the current availability of the vaccine, priority should be given to the populations most at risk, as defined by the health authorities. If the vaccine is indicated in a child, in a very rare or particular context of associated risk factors, it can be carried out.

For now, there is also no indication to vaccinate people in the family circle of a child with autoimmune cytopenia, unless they themselves have serious COVID risk factors. .

The decision to vaccinate is always discussed on a case-by-case basis, between the patient, his attending physician and his specialist referring physician.

Pending a possible evolution of the recommendations, it is necessary to remain vigilant and to ensure that the barrier gestures are respected.